Outcomes after a Uterine-Sparing Approach to Essure Contraceptive Device Removal.

JSLS

Division of Minimally Invasive Gynecologic Surgery, Department of Obstetrics & Gynecology and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.

Published: December 2022

Background And Objective: To analyze long-term effectiveness of a conservative, uterine-sparing approach to laparoscopic Essure removal. Specific outcomes of interest include patient satisfaction, symptom resolution, and subsequent surgical intervention.

Methods: A retrospective case series and follow-up survey. Patients who underwent laparoscopic Essure removal without concomitant hysterectomy between January 1, 2016 and December 31, 2019 were identified. Greater than 18 months after removal participants completed a survey assessing outcomes.

Results: Twenty-nine patients underwent conservative Essure removal and there were 19 survey respondents. Among survey respondents, the mean length of time from Essure placement to removal was 56.7 months (range 5 - 117), and the mean length of time from removal to survey administration was 48.3 months (range 23 - 63). The most frequently reported symptoms were pain (100%), bleeding (52.6%), headache (42.1%), and dyspareunia (42.1%). Methods for removal included laparoscopic salpingectomy (58.6%), a combined hysteroscopic and laparoscopic approach (34.4%), and cornuectomy (6.9%). Regarding symptom improvement after Essure removal, 47.4% of patients reported total improvement, 36.8% reported almost total improvement, 5.3% reported some improvement, and 10.5% reported no improvement. Most patients (89.5%) reported satisfaction with their surgical results, and only two patients required subsequent surgical intervention for symptom management.

Conclusions: Most patients in our cohort reported total or almost total improvement in symptoms almost two years after Essure removal, with low rates of reintervention. A uterine-sparing approach to Essure removal, using laparoscopic and hysteroscopic modalities, may be a feasible and effective approach to addressing Essure-attributed symptoms.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726173PMC
http://dx.doi.org/10.4293/JSLS.2022.00072DOI Listing

Publication Analysis

Top Keywords

essure removal
24
uterine-sparing approach
12
reported total
12
total improvement
12
removal
11
essure
8
approach essure
8
laparoscopic essure
8
subsequent surgical
8
patients underwent
8

Similar Publications

Article Synopsis
  • The study aimed to evaluate how effective surgical removal of Essure implants is for symptom relief and patient satisfaction both shortly after and six months post-surgery.
  • Conducted at Lille Regional University Hospital, the research involved women who had their Essure implants removed between 2016 and 2020, and included different types of surgery to perform the removal.
  • Results showed that 74% of patients experienced total symptom relief at six months, high patient satisfaction rates (97.3% would opt for the procedure again), and while many symptoms improved, some negative effects lingered.
View Article and Find Full Text PDF

Study Objective: Essure is a hysteroscopic sterilization device that has been used in the Netherlands since 2003. Essure has received a lot of publicity due to many reported symptoms associated with the device. Because of this, increasing numbers of patients requested surgical removal of Essure devices.

View Article and Find Full Text PDF

How to be sure of a complete removal of Essure® implant? A radiological study of Essure® microinserts.

J Gynecol Obstet Hum Reprod

November 2024

Department of Gynecology, Hôpital Femme Mère Enfant, HFME, University Hospital of Lyon, 59 boulevard Pinel, Lyon 69000, France.

Article Synopsis
  • Laparoscopic cornuectomy is commonly used to remove Essure® implants, but there's a risk of the device fragmenting, which can complicate surgery.
  • A study of 66 patients by gynecologists assessed the effectiveness of intraoperative radiographs compared to direct inspection of the removed implants to check for any remaining fragments.
  • Results showed that while the sensitivity and specificity were high for both methods, senior gynecologists performed better than residents, and postoperative imaging is still advised for thorough checking after the procedure.
View Article and Find Full Text PDF

A focal serous tubal intraepithelial lesion (STIL) is a rare lesion found on fallopian tubes that are characterized by atypical epithelial cells exhibiting morphological abnormalities with the accumulation of mutant p53 proteins. The p53 gene is a tumor suppressor gene, and when mutated gives rise to mutant p53 proteins that promote cancer cell growth and survival. We present a case of a 47-year-old gravida 2, para 2002 (G2P2) female who presented to the outpatient clinic with bilateral lower quadrant abdominal pain and back pain of four years' duration.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess the presence of adenomyosis in women who used the Essure® sterilization device and those undergoing hysterectomy for other benign reasons while experiencing pelvic pain and menstrual issues.
  • Conducted as a retrospective cohort study, it compared two groups: women with Essure devices who had symptoms and required hysterectomy, and women with similar symptoms but no device history.
  • Results showed a significantly higher prevalence of pelvic pain and adenomyosis in the Essure group, suggesting a potential association between the device and the development of adenomyosis, although causation remains unclear.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!